AVNS · As filed with the SEC
Avanos Medical income statement, by fiscal year
The statement as Avanos Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED INCOME (LOSS) STATEMENTS · USD, except per-share amounts
| USD, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Net Sales | 701,200,000 | 687,800,000 | 673,300,000 | 820,000,000 | 587,000,000 | 714,800,000 |
| Cost of products sold | 347,300,000 | 306,500,000 | 293,600,000 | 370,000,000 | 287,800,000 | 343,900,000 |
| Gross Profit | 353,900,000 | 381,300,000 | 379,700,000 | 450,000,000 | 299,200,000 | 370,900,000 |
| Research and development | 23,300,000 | 26,200,000 | 27,200,000 | 30,600,000 | 30,600,000 | 34,900,000 |
| Selling and general expenses | 315,600,000 | 318,500,000 | 335,000,000 | 341,900,000 | 285,300,000 | 332,600,000 |
| Goodwill and intangibles impairment | 77,000,000 | 436,700,000 | — | — | — | — |
| Other (income) expense, net | (400,000) | (3,900,000) | 13,300,000 | 3,500,000 | 22,300,000 | 51,900,000 |
| Operating (Loss) Income | (61,600,000) | (396,200,000) | 4,200,000 | 74,000,000 | (39,000,000) | (48,500,000) |
| Interest income | 3,200,000 | 5,100,000 | 2,900,000 | 1,200,000 | 200,000 | 1,200,000 |
| Interest expense | — | — | (15,000,000) | (10,000,000) | (3,300,000) | (15,600,000) |
| Interest expense | (7,800,000) | (12,200,000) | — | — | — | — |
| Loss Before Income Taxes | (66,200,000) | (403,300,000) | (7,900,000) | 65,200,000 | (42,100,000) | (62,900,000) |
| Income tax (provision) benefit | (6,700,000) | 17,000,000 | (2,000,000) | (14,700,000) | 11,200,000 | 33,900,000 |
| Loss from Continuing Operations | (72,900,000) | (386,300,000) | (9,900,000) | — | (30,900,000) | — |
| Loss from discontinued operations, net of tax | 0 | (5,800,000) | (51,900,000) | — | 37,200,000 | — |
| Net Loss | (72,900,000) | (392,100,000) | (61,800,000) | 50,500,000 | 6,300,000 | (29,000,000) |
| Loss Per Share | ||||||
| Basic: | ||||||
| Continuing operations (in dollars per share) | (1.57) | (8.40) | (0.21) | — | (0.64) | — |
| Discontinued operations (in dollars per share) | 0.00 | (0.13) | (1.11) | — | 0.77 | — |
| Basic Loss Per Share (in dollars per share) | (1.57) | (8.53) | (1.32) | 1.08 | 0.13 | (0.61) |
| Diluted: | ||||||
| Continuing operations (in dollars per share) | (1.57) | (8.40) | (0.21) | — | (0.64) | — |
| Discontinued operations (in dollars per share) | 0.00 | (0.13) | (1.11) | — | 0.77 | — |
| Diluted Loss Per Share (in dollars per share) | (1.57) | (8.53) | (1.32) | 1.07 | 0.13 | (0.61) |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.